Released May 27, 2016 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources, Incorporated (Sugar Land, Texas)--One of the Pharmaceutical-Biotech Industry's top three drug makers, Swiss-based Novartis International AG (NYSE:NVS) (Basel), has restructured its pharmaceuticals division by creating two business units--Novartis Pharmaceuticals and Novartis Oncology. Coinciding with the organizational split, the division head and chief executive officer of the company's Pharmaceuticals division, David Epstein, called it quits.
The two new business units will form the Innovative Medicines Division, with Novartis Pharmaceuticals operating under its new chief executive officer, Paul Hudson, and Bruno Strigini serving as the chief executive officer of Novartis Oncology. Both will report directly to Joseph Jimenez, chief executive officer of Novartis International.
The Novartis restructuring of oncology into a stand-alone unit underscores its importance to the company, following its $16 billion purchase of GlaxoSmithKline PLC's (NYSE:GSK) (London, England) cancer treatment assets in 2015. The company's remaining drugs will fall under the management of the Pharmaceutical unit.
Effective July 1, 2016, Novartis will operate under three distinct divisions; Innovative Medicines (formerly the Novartis Pharmaceuticals division), which will include the Novartis Pharmaceuticals and Novartis Oncology business units; Sandoz, the generics and biosimilar division, which includes the retail generics, anti-infectives and biopharmaceuticals franchises; and Alcon, the eye care devices division, which includes the surgical and vision care franchises.
Novartis kicked off the year with another major revamp, one that targeted Alcon. The company, acquired in 2010 for $50 billion from Nestle (Vevey, Switzerland), was underperforming in both innovation and profits. Alcon head Jeff George was replaced by Mike Ball, and the unit was pared down to oversight of contact lenses and cataract surgery equipment. The pharmaceutical unit absorbed all eye drug products.
ACTIVE NOVARTIS PROJECTS TRACKED BY INDUSTRIAL INFO
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
The two new business units will form the Innovative Medicines Division, with Novartis Pharmaceuticals operating under its new chief executive officer, Paul Hudson, and Bruno Strigini serving as the chief executive officer of Novartis Oncology. Both will report directly to Joseph Jimenez, chief executive officer of Novartis International.
The Novartis restructuring of oncology into a stand-alone unit underscores its importance to the company, following its $16 billion purchase of GlaxoSmithKline PLC's (NYSE:GSK) (London, England) cancer treatment assets in 2015. The company's remaining drugs will fall under the management of the Pharmaceutical unit.
Effective July 1, 2016, Novartis will operate under three distinct divisions; Innovative Medicines (formerly the Novartis Pharmaceuticals division), which will include the Novartis Pharmaceuticals and Novartis Oncology business units; Sandoz, the generics and biosimilar division, which includes the retail generics, anti-infectives and biopharmaceuticals franchises; and Alcon, the eye care devices division, which includes the surgical and vision care franchises.
Novartis kicked off the year with another major revamp, one that targeted Alcon. The company, acquired in 2010 for $50 billion from Nestle (Vevey, Switzerland), was underperforming in both innovation and profits. Alcon head Jeff George was replaced by Mike Ball, and the unit was pared down to oversight of contact lenses and cataract surgery equipment. The pharmaceutical unit absorbed all eye drug products.
| Project ID | Project TIV | Project Name |
|---|---|---|
| 300072903 | $550,000,000.00 | SOLID DOSE AND ASEPTIC PHARMACEUTICALS REPLACEMENT PLANT ADDITION |
| 300241510 | $250,000,000.00 | OPTICAL LENS PLANT UPFIT "PHASE II" AND CENTRAL UTILITIES BUILDING ADD |
| 300231394 | $100,000,000.00 | OPHTHALMIC SOLUTIONS ASPEX CAMPUS STERILE FILLING/PKG PLANT ADDITION |
| 300267734 | $88,000,000.00 | GENERIC DERMATOLOGY SEMI-SOLID TOPICALS PLANT FIT UP AND EXPANSION |
| 300263268 | $75,830,000.00 | VACCINES PLANT REFURBISHMENT |
| 300114284 | $50,000,000.00 | STERILE INJECTABLES & TABLETS PLANT EXPANSION |
| 300261562 | $15,610,000.00 | PHARMACEUTICALS INNOVATIVE DRUGS PRODUCTION EXPANSION |
| 300110647 | $14,610,000.00 | 5MW NATURAL GAS CHP PLANT ADDITION |
| 300261550 | $7,806,000.00 | PHARMACEUTICALS PRODUCTION LINE MODERNIZATION |
| 300263273 | $3,345,000.00 | PHARMACEUTICAL SOLID DOSE PACKAGING PLANT CLOSURE & DECOMMISSIONING |
| 300246890 | $3,000,000.00 | OPTICAL LENSES PLANT 4Q16 MAINTENANCE SHUTDOWN |
| 300261234 | $2,007,000.00 | PHARMACEUTICALS PACKAGING AND WAREHOUSE FACILITY EXPANSION |
| 300262679 | $2,000,000.00 | API PLANT 2016 MAINTENANCE SHUTDOWN |
| 300268206 | $2,000,000.00 | API PLANT 2017 MAINTENANCE PROGRAM |
| 300257528 | $2,000,000.00 | OPTICAL SURGICAL MEDICAL DEVICE PLANT 4Q16 MAINTENANCE SHUTDOWN |
| 300240235 | $2,000,000.00 | STERILE OPTHALMIC (EYE) SOLUTIONS PLANT 4Q16 MAINTENANCE SHUTDOWN |
| 300248089 | $2,000,000.00 | GENERICS PHARMACEUTICAL PLANT 3Q16 MAINTENANCE S/D |
| 300262307 | $1,500,000.00 | API'S PLANT 2016 MAINTENANCE PROGRAM |
| 300230856 | $1,200,000.00 | OPHTHALMIC (EYE) SOLUTIONS 3Q16 MAINTENANCE SHUTDOWN |
| 300260462 | $1,115,000.00 | AM MAIN INTERMEDIATES AND API'S CMO PLANT CLOSURE |
| 300256743 | $1,000,000.00 | LENSES & MEDICAL DEVICES PLANT 2016 MAINTENANCE PROGRAM |
| 300114302 | $1,000,000.00 | STERILE INJECTABLES & TABLETS PLANT UNIT 2 CLOSURE |
| 300255381 | $1,000,000.00 | INTRAOCULAR MEDICAL PLANT 4Q16 MAINTENANCE SHUTDOWN |
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.
